Achieving a pCR in HER2-positive patients results in a significantly better event-free and overall survival as shown in the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) pooled analysis [5]. This evidence concerns the gene ERBB2 and breast carcinoma.